Development and validation of a stability-indicating RP-HPLC method for estimation of Lefamulin in pure and pharmaceutical drug products

Future Journal of Pharmaceutical Sciences

Table 3 Recovery results of the proposed method

Time intervals	Spiked level (%)	Recovery of respective level		Recovery^a (%)
Time intervals	Spiked level (%)	Tablet	Injection	Tablet	Injection
Repeatability	80	80.52	80.47	100.65	100.59
	100	99.69	100.69	99.69	100.69
	120	120.02	119.79	100.02	99.83
Day 01	80	79.56	80.69	99.45	100.86
	100	100.64	99.45	100.64	99.45
	120	120.14	119.98	100.12	99.98
Day 02	80	81.02	79.09	101.28	98.86
	100	100.69	99.36	100.69	99.36
	120	120.51	120.04	100.43	100.03
Day 03	80	79.69	81.45	99.61	101.81
	100	99.98	101.41	99.98	101.41
	120	119.37	120.27	99.48	100.23
Average recovery (acceptance criteria 98% to 102%)				100.17%	100.26%
% RSD of recovery (should be not more than 2%)				0.572%	0.857%